EGFR and non-small cell lung carcinoma: On the basis of the favorable results of prospective randomized trials, EGFR TKIs are now recommended as a standard first-line treatment replacing conventional platinum-based chemotherapy for patients with EGFR-mutated NSCLC (15–20).